[HTML][HTML] Small molecules containing chalcogen elements (S, Se, Te) as new warhead to fight neglected tropical diseases

A Henriquez-Figuereo, C Morán-Serradilla… - European Journal of …, 2023 - Elsevier
Neglected tropical diseases (NTDs) encompass a group of infectious diseases with a
protozoan etiology, high incidence, and prevalence in developing countries. As a result …

Advances in preclinical approaches to Chagas disease drug discovery

F Villalta, G Rachakonda - Expert opinion on drug discovery, 2019 - Taylor & Francis
ABSTRACT Introduction: Chagas disease affects 8–10 million people worldwide, mainly in
Latin America. The current therapy for Chagas disease is limited to nifurtimox and …

Sialidase and sialyltransferase inhibitors: targeting pathogenicity and disease

WHD Bowles, TM Gloster - Frontiers in Molecular Biosciences, 2021 - frontiersin.org
Sialidases (SAs) and sialyltransferases (STs), the enzymes responsible for removing and
adding sialic acid to other glycans, play essential roles in viruses, bacteria, parasites, and …

Recent advances in the development of triose phosphate isomerase inhibitors as antiprotozoal agents

LK Vázquez-Jiménez, A Moreno-Herrera… - Current Medicinal …, 2022 - ingentaconnect.com
Background: Parasitic diseases caused by protozoa, such as Chagas disease,
leishmaniasis, malaria, African trypanosomiasis, amoebiasis, trichomoniasis, and giardiasis …

Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies

I Palos, EE Lara-Ramirez, JC Lopez-Cedillo… - Molecules, 2017 - mdpi.com
Chagas disease (CD) is a neglected disease caused by the parasite Trypanosoma cruzi,
which affects underdeveloped countries. The current drugs of choice are nifurtimox and …

Theft and Reception of Host Cell's Sialic Acid: Dynamics of Trypanosoma Cruzi Trans-sialidases and Mucin-Like Molecules on Chagas' Disease Immunomodulation

LM Fonseca, KM da Costa, VS Chaves… - Frontiers in …, 2019 - frontiersin.org
The last decades have produced a plethora of evidence on the role of glycans, from cell
adhesion to signaling pathways. Much of that information pertains to their role on the …

Novel atorvastatin-curcumin conjugate nanogel, a selective COX2 inhibitor with enhanced biopharmaceutical profile: Design, synthesis, in silico, in vitro, and in vivo …

R Dash, J Biswal, M Yadav, T Sharma… - Journal of Drug Delivery …, 2023 - Elsevier
In the current research, the main attention was to overcome solubility related issues of
atorvastatin (AC), and curcumin (CUR) through atorvastatin-curcumin conjugate (AC-CUR) …

Structure-Based Virtual Screening and In Vitro Evaluation of New Trypanosoma cruzi Cruzain Inhibitors

V Herrera-Mayorga, EE Lara-Ramírez… - International journal of …, 2019 - mdpi.com
Chagas disease (CD), or American trypanosomiasis, causes more than 10,000 deaths per
year in the Americas. Current medical therapy for CD has low efficacy in the chronic phase …

The thiol-polyamine metabolism of Trypanosoma cruzi: molecular targets and drug repurposing strategies

A Talevi, C Carrillo, M Comini - Current Medicinal Chemistry, 2019 - ingentaconnect.com
Chagas´ disease continues to be a challenging and neglected public health problem in
many American countries. The etiologic agent, Trypanosoma cruzi, develops intracellularly …

In silico drug repositioning for Chagas disease

CL Bellera, LN Alberca, ML Sbaraglini… - Current Medicinal …, 2020 - ingentaconnect.com
Chagas disease is an infectious tropical disease included within the group of neglected
tropical diseases. Though historically endemic to Latin America, it has lately spread to high …